Recombinant Mouse Probable G-protein coupled receptor 160 (Gpr160)

Introduction to G-protein Coupled Receptor 160 (Gpr160)

G-protein Coupled Receptor 160 (Gpr160) belongs to the extensive family of G protein-coupled receptors that feature seven transmembrane domains and function by transducing extracellular signals through heterotrimeric G proteins . This receptor has garnered significant attention in recent years due to its potential role in nociception and pain processing. Structurally, Gpr160 is classified as a Class A (Rhodopsin) GPCR according to the standardized GPCR classification system . The significance of this receptor has been highlighted through knockout studies demonstrating its critical involvement in pathological pain states.

The gene encoding Gpr160 in mice is also known by synonyms including 1700025D19Rik and GPCR150, reflecting its historical identification before its function was fully understood . Until recently, Gpr160 remained an orphan receptor with no identified endogenous ligand, limiting understanding of its physiological functions. A significant breakthrough occurred when researchers identified cocaine- and amphetamine-regulated transcript peptide (CARTp) as a potential ligand for Gpr160, effectively "deorphanizing" this receptor and providing crucial insights into its functional role .

Gpr160 knockout mice have been generated using CRISPR-Cas9 genome editing technology to validate the contributions of this receptor in nociceptive behaviors. These knockout mice are healthy, fertile, and show no observable physical abnormalities, suggesting that Gpr160 is not essential for normal development or basic physiological functions . This characteristic makes Gpr160 particularly interesting as a potential therapeutic target, as targeting it may not disrupt essential physiological processes.

Molecular Structure and Characteristics of Mouse Gpr160

The molecular structure of mouse Gpr160 conforms to the canonical GPCR architecture, featuring seven transmembrane helices connected by intracellular and extracellular loops. As a Class A (Rhodopsin) GPCR, it shares structural similarities with other members of this largest and most extensively studied GPCR family . Structure modeling of Gpr160 has revealed varying confidence levels in different regions of the protein, with most areas displaying "very high" to "confident" prediction scores according to AlphaFold pLDDT (predicted Local Distance Difference Test) metrics .

Mouse Gpr160 exists in multiple transcript variants, with transcript variant 1 being commonly used in research applications and commercial products . The full-length protein contains the characteristic GPCR features necessary for ligand binding and signal transduction. Recombinant expression of mouse Gpr160 has been achieved in various systems, including E. coli, yeast, baculovirus, and mammalian cell systems, each offering different advantages for specific research applications .

The structure of Gpr160 is particularly important for understanding its function in nociceptive neurons. The receptor's transmembrane domains form a binding pocket for potential ligands, while intracellular regions interact with G proteins and other signaling molecules. Detailed structural understanding of Gpr160 continues to evolve, with recent advancements in computational modeling providing increasingly accurate predictions of receptor conformation and dynamics.

Functional Role of Gpr160 in Pain Signaling

The functional significance of Gpr160 has been most clearly demonstrated in pain processing pathways. Knockout studies have provided compelling evidence that Gpr160 plays a critical role in the development of pathological pain states while having minimal impact on normal nociception. Gpr160 knockout mice fail to develop behavioral hypersensitivities in models of neuropathic pain caused by constriction of the sciatic nerve, while their responses in hot-plate and tail-flick assays remain unaffected . This selective involvement in pathological pain makes Gpr160 a particularly attractive therapeutic target.

The identification of CARTp as a potential ligand for Gpr160 has further elucidated its functional role. Using Gpr160 knockout mice, researchers demonstrated that the development of behavioral hypersensitivities after intrathecal or intraplantar injections of CARTp is dependent on Gpr160 . This finding establishes a clear link between CARTp signaling and Gpr160 activation in pain processing. Interestingly, although CARTp plays roles in various affective behaviors such as anxiety, depression, and cognition, Gpr160 knockout mice show no differences in learning, memory, or anxiety compared to control mice . This suggests that Gpr160 may mediate specific aspects of CARTp signaling related to nociception, rather than its effects on mood or cognition.

Beyond neuropathic pain, Gpr160 has been implicated in cancer-related pain. Studies have shown that elevated Gpr160 expression in dorsal root ganglion (DRG) neurons contributes to bone cancer pain (BCP) in rodents . The overexpression of Gpr160 in DRG neurons via viral vectors induces nociceptive hypersensitivity to mechanical, heat, and cold stimuli, as well as anxiety-like behavior during evoked responses . These findings further support the pronociceptive role of Gpr160 across multiple pain modalities.

Recombinant Forms of Mouse Gpr160

Recombinant mouse Gpr160 proteins have become essential tools for investigating receptor function, interactions, and potential therapeutic applications. Various expression systems have been employed to produce recombinant Gpr160, each with specific advantages for different research applications. The table below summarizes commercially available recombinant mouse Gpr160 products:

These recombinant proteins vary in design and intended use. Full-length recombinant Gpr160 can be challenging to express due to its transmembrane nature, which is why partial constructs are also commonly used. The choice of expression system significantly affects protein folding, post-translational modifications, and functional properties. E. coli-based systems provide high yield but may lack appropriate post-translational modifications, while mammalian expression systems offer more native-like protein processing but with typically lower yields .

Tagged versions of recombinant Gpr160, such as tGFP-tagged constructs, facilitate detection and localization studies in cellular models . These tagged proteins enable visualization of receptor distribution, trafficking, and co-localization with other cellular components. Expression-ready ORF plasmids allow researchers to transfect cells and study receptor function in various experimental contexts.

Neurophysiological Effects of Gpr160 Modulation

Electrophysiological studies have provided crucial insights into how Gpr160 affects neuronal function, particularly in the context of pain processing. Research has demonstrated that Gpr160 is required for DRG neuronal hyperexcitability induced by bone cancer pain. Neurons from Gpr160 knockout mice exhibit notably elevated action potential threshold and rheobase compared to control wild-type neurons in bone cancer pain models . Additionally, the frequency and number of action potentials in Gpr160 knockout mice were decreased relative to controls .

Conversely, overexpression of Gpr160 in cultured DRG neurons results in enhanced excitability. Gpr160-overexpressing neurons show reduced action potential threshold and rheobase, along with increased frequency and count of action potentials . These findings establish a direct link between Gpr160 expression levels and neuronal excitability, providing a mechanistic explanation for the pronociceptive effects of this receptor.

The electrophysiological changes mediated by Gpr160 have significant implications for pain processing. By modulating the excitability of nociceptive neurons, Gpr160 directly influences pain signaling pathways. The hyperexcitability induced by Gpr160 activation likely contributes to the development and maintenance of pathological pain states, including both neuropathic pain and cancer-related pain. This mechanistic understanding strengthens the rationale for targeting Gpr160 in pain management strategies.

Molecular Regulation of Gpr160 Expression

The expression of Gpr160 is regulated by multiple mechanisms, including epigenetic modifications and transcription factor activity. Research has revealed significant changes in histone modifications at the Gpr160 promoter region during bone cancer pain. Specifically, a reduction in the repressive histone mark H3K27me3 and an increase in the activating mark H3K27ac have been observed, suggesting epigenetic regulation of Gpr160 expression .

The transcription factor Sp1 has been identified as a key regulator of Gpr160 gene transcription in nociceptive DRG neurons during bone cancer pain in rodents . Elevated Sp1 levels facilitate increased Gpr160 expression, contributing to pain hypersensitivity. This finding delineates a novel mechanism wherein Sp1 works in conjunction with altered histone modifications to upregulate Gpr160 in pathological pain states.

Understanding these regulatory mechanisms provides potential alternative approaches for therapeutic intervention. Rather than targeting Gpr160 directly, modulating the upstream factors controlling its expression could offer effective strategies for pain management. Epigenetic modifiers targeting histone modifications or inhibitors of Sp1 activity could potentially normalize Gpr160 expression and alleviate pain hypersensitivity.

Experimental Applications of Recombinant Mouse Gpr160

Recombinant mouse Gpr160 has diverse applications in experimental research, enabling investigations that would be challenging with the native receptor due to expression levels or technical limitations. These applications span from basic research to drug discovery efforts.

Ligand binding studies represent a primary application for recombinant Gpr160. Purified recombinant receptor can be used in binding assays to identify and characterize interactions with potential ligands, including both natural molecules like CARTp and synthetic compounds. These studies are crucial for understanding receptor pharmacology and developing potential therapeutic agents.

Structural investigations benefit significantly from recombinant Gpr160 production. While the search results do not indicate that crystal structures have been determined for Gpr160, computational models have been developed to predict its structure . Recombinant protein production is typically a prerequisite for experimental structure determination using techniques such as X-ray crystallography or cryo-electron microscopy.

Overexpression studies using Gpr160 constructs provide valuable insights into receptor function in cellular contexts. The availability of expression plasmids, such as the tGFP-tagged mouse Gpr160 construct, enables researchers to introduce the receptor into various cell types and observe resulting changes in cellular function and signaling . Such studies have demonstrated that Gpr160 overexpression enhances neuronal excitability and promotes pain hypersensitivity .

Antibody development and validation represent another important application for recombinant Gpr160. Purified recombinant proteins serve as antigens for generating specific antibodies, which are essential tools for detecting and studying the receptor in tissues and cells. Commercial antibodies against human GPR160 are available and have been validated for applications including Western blotting, immunohistochemistry, immunofluorescence, and ELISA .

Therapeutic Potential of Gpr160 Targeting

The findings from Gpr160 knockout studies highlight this receptor's significant potential as a therapeutic target for pain management. The selective involvement of Gpr160 in pathological pain states, rather than normal nociception, suggests that targeting this receptor could provide effective pain relief with minimal disruption of normal sensory function.

The most compelling evidence for Gpr160's therapeutic potential comes from neuropathic pain models. Gpr160 knockout mice fail to develop behavioral hypersensitivities in a model of neuropathic pain caused by constriction of the sciatic nerve, while maintaining normal responses in acute pain assays . This selective effect on pathological pain makes Gpr160 an attractive target for developing novel analgesics with potentially improved side effect profiles compared to current options.

Similarly, in bone cancer pain models, global knockout of Gpr160 mitigates pain without altering normal nociceptive thresholds . These findings suggest that antagonists of Gpr160 might effectively alleviate cancer-related pain, which often responds poorly to conventional analgesics. The identification of CARTp as a ligand for Gpr160 provides additional avenues for therapeutic development, as targeting the CARTp-Gpr160 interaction could offer another approach to modulating this signaling pathway.

The results from these studies collectively support the pronociceptive roles of CARTp/GPR160 and establish GPR160 as a potential therapeutic target for the treatment of neuropathic pain . As neuropathic pain represents a significant clinical challenge with limited effective treatment options, the development of Gpr160-targeting therapeutics could address an important unmet medical need.

Future Directions in Gpr160 Research

Research on Gpr160 continues to evolve, with several promising directions for future investigation. Development of selective Gpr160 antagonists represents a particularly promising approach. Given the selective involvement of Gpr160 in pathological rather than physiological pain, antagonists could potentially provide effective pain relief with minimal side effects. The results from knockout studies support this approach, as Gpr160 knockout mice maintain normal responses to acute pain stimuli while showing resistance to pathological pain development .

Deeper characterization of the interaction between CARTp and Gpr160 is another important area for future research. While CARTp has been identified as a ligand for Gpr160, the detailed molecular mechanisms of this interaction and downstream signaling consequences remain to be fully elucidated. Understanding these details could facilitate the development of more selective and effective therapeutic agents.

Exploring the potential involvement of Gpr160 in additional physiological and pathological processes also warrants investigation. While current research has focused primarily on pain signaling, GPCRs typically participate in multiple biological functions. Comprehensive phenotyping of Gpr160 knockout models beyond pain behaviors could reveal additional roles for this receptor.

Translational research exploring the relevance of Gpr160 to human pain conditions represents a critical future direction. While mouse models have provided valuable insights, confirming similar mechanisms in human tissues will be essential for therapeutic development. Comparative studies of human and mouse GPR160 could help determine the translational potential of findings from rodent models.